Tong Ren Tang Technologies Co. Ltd. announced that the pharmaceutical factory of the Company recently received the Notice of Approval for Clinical Trial of Medicine (Yao Wu Lin Chuang Shi Yan Pi Zhun Tong Zhi Shu) issued by the National Medical Products Administration. Details are as follows: Basic information of the medicine: Qishen Granules (Qi Can Ke Li) Applicant: Tong Ren Tang Technologies Co.

Ltd.'s Pharmaceutical Factory. Category of registration: Registration category 1.1 of traditional Chinese medicines. Indications: Benefiting qi and warming yang, and promoting blood circulation and detoxication.

Curing for the syndrome of chronic heart failure due to qi deficiency and blood stasis. Acceptance number: CXZL2300074. Notice number: 2024LP00491.

Review conclusion: According to the Drug Administration Law of the People's Republic of China () /V Vaccine Administration Law of the People'sRepublic of China (Zhong Hua Ren Minong He Guo Yi Miao Guan Li Fa >) and relevant regulations, Qishen Granules (Qi Can Ke Li) was approved to use in clinical trial for chronic heart failure with reduced ejection fraction. Research and development of the medicine and related information. The Qishen Granules ("Qi Can Ke Li") applied for clinical trial by the pharmaceutical factory of the Company is a traditional Chinese medicine compound preparation, which is applied according to the registration category 1.1 of traditional Chinese medicines and is intended to be used for chronic heart failure syndrome of qi deficiency and bloodstasis.

As at the date of this announcement, the Company has invested approximately RMB 7.8 million (unaudited) in the research and development of Qi Can Ke Li). Risk warning: In accordance with the requirements of the relevant laws and regulations on registration of medicine in the PRC, a clinical trial of medicine shall be performed upon receiving the approval for the clinical trial and the medicine shall be produced and marketed only upon being assessed and scrutinized by the National Medical Products Administration. Given its special nature and long cycle from clinical trials to production upon approval which involves many stages, the research and development of medicine are susceptible to many unpredictable factors.

There are uncertainties in the progress and results of clinical trials and the future competitive landscape of the pharmaceutical market. Investors are advised to consider the risks involved and be cautious in making investment decisions.